These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9531302)

  • 21. Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity.
    Yang ZM; Li EM; Lai BC; Wang YL; Si LS
    Biochem Cell Biol; 2007 Apr; 85(2):196-202. PubMed ID: 17534400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
    van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
    J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
    Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
    J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
    Liu A; Hu P; Khawli LA; Epstein AL
    J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells.
    Galea-Lauri J; Darling D; Gan SU; Krivochtchapov L; Kuiper M; Gäken J; Souberbielle B; Farzaneh F
    J Immunol; 1999 Jul; 163(1):62-70. PubMed ID: 10384100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and characterization of glycolipid-anchored B7-1 (CD80) from baculovirus-infected insect cells: protein transfer onto tumor cells.
    Nagarajan S; Selvaraj P
    Protein Expr Purif; 1999 Nov; 17(2):273-81. PubMed ID: 10545276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation.
    Baban B; Hansen AM; Chandler PR; Manlapat A; Bingaman A; Kahler DJ; Munn DH; Mellor AL
    Int Immunol; 2005 Jul; 17(7):909-19. PubMed ID: 15967784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
    Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
    Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG; Turcovski-Corrales SM; Taub DD
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination.
    Zhou ZF; Peretz Y; Chang Y; Miao DS; Li X; Prud'homme GJ
    Cancer Gene Ther; 2003 Jun; 10(6):491-9. PubMed ID: 12768195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS; Morrison SL; Penichet ML
    Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
    Dong H; Zhu G; Tamada K; Chen L
    Nat Med; 1999 Dec; 5(12):1365-9. PubMed ID: 10581077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway.
    Ou D; Wang X; Metzger DL; Ao Z; Pozzilli P; James RF; Chen L; Warnock GL
    Cell Transplant; 2006; 15(5):399-410. PubMed ID: 16970282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
    Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
    Dong H; Strome SE; Salomao DR; Tamura H; Hirano F; Flies DB; Roche PC; Lu J; Zhu G; Tamada K; Lennon VA; Celis E; Chen L
    Nat Med; 2002 Aug; 8(8):793-800. PubMed ID: 12091876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
    Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
    Orlandi F; Venanzi FM; Concetti A; Yamauchi H; Tiwari S; Norton L; Wolchok JD; Houghton AN; Gregor PD
    Clin Cancer Res; 2007 Oct; 13(20):6195-203. PubMed ID: 17947487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
    Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
    J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.